Skribek, M.; Rounis, K.; Makrakis, D.; Agelaki, S.; Mavroudis, D.; De Petris, L.; Ekman, S.; Tsakonas, G.
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting. Cancers 2020, 12, 3707.
https://doi.org/10.3390/cancers12123707
AMA Style
Skribek M, Rounis K, Makrakis D, Agelaki S, Mavroudis D, De Petris L, Ekman S, Tsakonas G.
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting. Cancers. 2020; 12(12):3707.
https://doi.org/10.3390/cancers12123707
Chicago/Turabian Style
Skribek, Marcus, Konstantinos Rounis, Dimitrios Makrakis, Sofia Agelaki, Dimitris Mavroudis, Luigi De Petris, Simon Ekman, and Georgios Tsakonas.
2020. "Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting" Cancers 12, no. 12: 3707.
https://doi.org/10.3390/cancers12123707
APA Style
Skribek, M., Rounis, K., Makrakis, D., Agelaki, S., Mavroudis, D., De Petris, L., Ekman, S., & Tsakonas, G.
(2020). Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting. Cancers, 12(12), 3707.
https://doi.org/10.3390/cancers12123707